Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Migraine Disorders, Date of authorisation: 14/11/2018, Revision: 1, Status: Authorised
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
